Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia.

Objectives Anthracyclines and cytarabine are cornerstones for intensive chemotherapy in acute myeloid leukemia (AML). The goals of this study were to comprehensively assess deviations from theoretical doses and the impact of body-surface area (BSA) on patients’ characteristics, physicians’ strategy, dose adjustment, and clinical outcome. Methods The GOELAMS 2001 phase III trial included 823 AML patients below 60 years of age. In the course of treatment, anthropomorphic parameters and chemotherapy doses were prospectively registered. Results Very high BSA (≥2.15 m2) was the factor most significantly associated with the physician's decision to reduce chemotherapy doses during induction and postremission therapy. Despite similar AML characteristics and therapeutic strategies, the very high BSA group exhibited a significantly worse survival (5-years OS of 27%) compared to the low (BSA≤1.5 m2), intermediate (1.5 m2

Keywords:

• Diabetes mellitus
• Immunology
• Body surface area
• Cytarabine
• Myeloid leukemia
• Medicine
• Chemotherapy
• Postremission Therapy
• Young adult
• younger adults
• Survival analysis

• Correction
• Source
• Cite
• Save
• Machine Reading By IdeaReader